GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK Vaccines’ shingles ad campaign warns about the year-round threat
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
MarketWatch14h
GSK falls Wednesday, underperforms market
GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...
FierceBiotech1d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Hosted on MSN16h
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
STAT3d
Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
FiercePharma1d
GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
FiercePharma5d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
BioPharma Dive1d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Affordable generics will stay relevant amid a premiumisation trend: GSK’s Bhushan Akshikar
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
GSK’s Trelegy TV ad depicts the reality of living with COPD
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
Pharmabiz3h
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
GSK announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary ...